Expand NRIX Menu
NRIX MENU

NRIX Latest Press Releases

-- December 24, 2025 --

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge Globe Newswire 6:00 AM

-- December 8, 2025 --

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenstrm Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Globe Newswire 8:00 AM

-- December 6, 2025 --

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition Globe Newswire 9:30 AM

-- December 1, 2025 --

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Globe Newswire 7:00 AM

-- November 25, 2025 --

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference Globe Newswire 7:00 AM

-- November 10, 2025 --

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors Globe Newswire 7:00 AM

-- November 7, 2025 --

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling Globe Newswire 9:00 AM

-- November 3, 2025 --

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting Globe Newswire 9:00 AM

-- October 30, 2025 --

Nurix Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- October 27, 2025 --

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock Globe Newswire 7:00 AM

-- October 22, 2025 --

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock Globe Newswire 7:20 AM
Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia Globe Newswire 6:00 AM

-- October 18, 2025 --

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress Globe Newswire 3:00 AM

-- October 9, 2025 --

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Globe Newswire 4:01 PM

-- September 17, 2025 --

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis Globe Newswire 7:00 AM

-- August 28, 2025 --

Nurix Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes